Glucocorticoids in cancer therapy

Udkow G. Steroid effects on leococyte counts. Drug Ther 1978; 8: 172–7. Peters WP, Holland JF, Senn H et al. Corticosteroid administration and localised leucocyte mobilization in man. N Engl J Med 1972; 282: 342–5. Weinberger C, Hollenberg SM, Rosenfield MG et al. Domain structure of human glucocorticoid receptor and its relationship to the v-erb-a oncogene product. Nature 1985; 318: 670–2. Henderson ES. Treatment of acute leukaemia. Seminarsin Haematology 1969; 6: 271. Thompson EB, Smith JR, Bourgeois S et al. Glucocorticoid receptors in human leukaemias and related diseases. Klin Wochenschr 1985; 63: 689–98. Yarbro GS, Lippman ME, Johnson GE et al. Glucocorticoid receptors in subpopulations of childhood acute lymphoblastic leukaemia. Cancer Res 1977; 37: 2688–95. Riehm H, Freikert H-H, Schrappe M et al. Treatment results of five ALL-BFM studies since 1970: implications of risk factors for prognosis. Haematol Blood Trans 1987; 30: 139–46. Jones B, Shuster JJ, Holland JF. Lower incidence of meningeal leukaemia when dexamethasone is substituted for prednisone in the treatment of acute lymphocytic leukaemia. Proc Am Assoc Clin Oncol 1984; 3: 191. Balis FM, Lester CM, Chrousos GP et al. Differences in cerebrospinal fluid penetration of corticosteroids: possible relationship to prevention of meningeal leukaemia. J Clin Oncol 1987; 5: 202–7. Gottlieb AJ, Weinberg V, Ellison RR et al. Efficacy of daunorubicin in the therapy of adult lymphocytic leukaemia: a prospective randomised trial by Cancer and Leukaemia Group B (CALGB). Blood 1984; 64: 267. Galton DAG, Wiltshaw E, Szur L et al. The use of chlorambucil and steroids in the treatment of chronic lymphocytic leukaemia. Br J Haematol 1961; 7: 73. Ezdinli EZ, Loeb V, Dorfman R et al. Corticosteroid therapy for lymphomas and chronic lymphocytic leukaemia. Cancer 1969; 23: 900. Sawitzy A, Rai KR, Glidewell O et al. Comparison of daily versus intermittent chlorambucil and prednisone therapy in the treatment of patients with chronic lymphocytic leukaemia. Blood 1977; 50: 1049. French Cooperative Group on Chronic Lymphocytic leukaemia. Effectiveness of “CHOP” regimen in advanced untreated chronic lymphocytic leukaemia. Lancet 1986; i: 1346. Todd M, Cadman E, Spiro P et al. A follow-up of a randomised study comparing two chemotherapy treatments for advanced diffuse histiocytic lymphoma. J Clin Oncol 1984; 2: 986–93. Gaynor ER, Rainey M, Dandy M et al. Treatment of diffuse histiocytic lymphoma (DHL) with COMLA: a 10 year experience in a single institution. J Clin Oncol 1985; 3: 1188–95. Portlock CS, Rosenberg SA, Glatsetin E et al. Treatment of advanced non-Hodgkin's lymphomas with favourable histologies: preliminary results of a prospective trial. Blood 1976; 47: 747. Lister TA, Cullen MH, Beard MEJ. Comparison of combined and single agent chemotherapy in non-Hodgkin lymphoma of favourable histological type. B Med J 1978; 1: 533. Peterson BA, Frizzera G, Anderson JR et al. Response of low grade lymphomas to cyclophosphamide (CTX) or cyclophosphamide, adriamycin, vincristine, prednisolone and bleomycin (CAVPB). Proc ASCO 1985; 4: C-822. British National Lymphoma Investigation. Value of prednisolone in stage IV Hodgkin's disease. Br Med J 1975; 3: 413. Salmon SE, Shadduck RK, Schilling A. Intermittent high-dose prednisone therapy for multiple myeloma. Cancer Chemother Rep 1967; 51: 179. Alexanian R, Barlogie B, Dixon D. High-dose glucocorticoid treatment of resistant myeloma. Annals Internal Medicine 1986; 105: 8–11. Dalton WS, Durie BGM, Alberts DS et al. Characterization of a new drug-resistant human myeloma cell line which expresses p-glycoprotein. Cancer Res 1986; 45: 5125–30. Barlogie B, Smith L, Alexian R. Effective treatment of advanced multiple myeloma refractory to alkylating agents. N Engl J Med 1984; 310: 1353–6. Minton MJ, Knight RK, Rubens RD, Hayward JL. Corticosteroids for elderly patients with breast cancer. Cancer 1981; 48: 883–7. Rees LH, Lowry PJ. Adrenocorticotrophin and lipotrophin. In: Gray CH and James VHT, eds. Hormones in blood. 3rd ed. London: Academic Press, 1979: 130–72. Whittliff J, Savlov G. Biochemical basis for the selection of hormonal manipulation in the patient with breast cancer. Int J Radiat Oncol Phys 1978; 4: 463–7. Lippman ME, Osborne CK, Knazek R et al.In vitro model systems for the study of hormone-dependent human breast cancer. New Engl J Med 1977, 296: 154–9. Blackburn AM, Wang DY, Bulbrook RD et al. Effect of prednisolone on hormone profiles during primary endocrine treatment of advanced breast cancer. Cancer Treat Rep 1984; 68: 1447–53. Nissen-Meyer R, Sanner T. The excretion of oestrone, prenanediol and pregnanetriol in breast cancer patients II. Effect of ovariectomy, ovarian ablation and corticosteroids. Acta Endocrinol 1963; 44: 334–45. Moore JW, Clark GMG, Bulbrook RD et al. Serum concentrations of total and non-protein bound oestradiol in patients with breast cancer and normal controls. Int J Cancer 1982; 29: 17–21. Wang DY, Rubens RD, Clark GMG et al. Effects of prednisolone on sex hormone binding globulin during primary treatment of advanced breast cancer. Breast Cancer Res Treat 1988; 11: 67. Stewart JF, Rubens RD, King RJB et al. Contribution of prednisolone to the primary endocrine treatment of advanced breast cancer. Eur J Cancer Clin Oncol 1982; 18: 1307–14. Rubens RD, Tinson CJ, Coleman RE et al. Prednisolone improves the response to primary endocrine treatment for advanced breast cancer. Br J Cancer 1988; 58: 626–30. Stuart-Harris RC, Smith IE. Aminoglutethimide in the treatment of advanced breast cancer. Cancer Treat Rev 1984; 11: 189–204. Meakin JW, Allt WEC, Bealk FA et al. Ovarian irradiation and prednisolone therapy following surgery and radiotherapy for carcinoma of the breast. Can Med Assoc J 1979; 120: 1221. Ludwig Breast Cancer Study Group. A randomised trial of adjuvant combination chemotherapy with or without prednisone in premenopausal breast cancer patients with metastases in one to three axillary lymph nodes. Cancer Research 1985; 45: 4454–9. Tormey DC, Gelman R, Band P et al. Comparison of single to alternating combination therapy in metastatic breast cancer. Proc Am Assoc Cancer Res 1980; 21: 171. Reulen HJ, Tsuyumu M, Tack A. Clearance of oedema fluid into CSF: a mechanism for resolution of vasogenic brain oedema. J Neurosurg 1978; 48: 754–64. Weissman DE. Glucocorticoid treatment for brain metastases and epidural spinal cord compression: a review. J Clin Oncol 1988; 6: 543–51. Schwartz ML, Tator CH, Hoffman HJ. The uptake of hydrocortisone in mouse brain and ependymoblastoma. J Neurosurg 1972; 36: 178–83. Posner JB. Diagnosis and treatment of metastases to the brain. Clin Bull 1974; 4: 47–57. Matsuoka S, Arakaki Y, Numaguchi K et al. The effect of dexamethasone on electroencephalograms in patients with tumours. With special reference to topographic computer display of delta activity. J Neurosurg 1978; 48: 601–8. Marty R, Cain ML. Effects of corticosteroids (dexamethasone) administration on the brain scan. Radiology 1973; 107: 117–21. Hatam A, Bergstrom M, Yu Z-Y et al. Effect of dexamethasone treatment on volume and contrast enhancement of intracranial neoplasms. J Comput Assist Tomogr 1983; 7: 295–300. French LA, Galicich JH. The use of steroids for control of cerbral oedema. Clin Neurosurg 1964; 10: 212–23. Renaudin J, Fewer D, Wilson CB et al. Dose-dependency of Decadron in patients with partially excised brain tumours. J Neurosurg 1973; 39: 302–5. Cairncross JG, Kim JH, Posner JB. Radiation therapy for brain metastases. Ann Neurol 1980; 7: 529–41. Ikeda H, Ushio Y, Hayakawa T et al. Oedema and circulatory disturbances in the spinal cord compressed by epidural neoplasms in rabbits. J Neutrosurg 1980; 52: 203–9. Greenberg HS, Kim J-H, Posner JB. Epidural spinal cord compression from metastatic tumour. Results with a new treatment protocol. Ann. Neurol 1980; 47: 380–90. Rubin P. Extradural spinal cord compression by tumour. Radiology 1969; 93: 1243–60. Percival RC, Yates AJP, Gray RES et al. Role of glucocorticoids in management of malignant hypercalcaemia. Br Med J 1984; 289: 287.